The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions

While anti-CD47 antibodies hold promise for cancer immunotherapy, early phase clinical trials have shown limited signs of clinical benefit, suggesting that blockade of CD47 alone may not be sufficient for effective tumor control. Here, we investigate the contributions of the Fc domain of anti-CD47 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Osorio, Juan C., Smith, Patrick, Knorr, David A., Ravetch, Jeffrey V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347539/
https://www.ncbi.nlm.nih.gov/pubmed/37455857
http://dx.doi.org/10.1101/2023.06.29.547082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347539/
https://www.ncbi.nlm.nih.gov/pubmed/37455857
http://dx.doi.org/10.1101/2023.06.29.547082

Ejemplares similares